Navigation Links
Bioheart Strengthens Executive Team in Order to Accelerate Business Plan and Enhance Its Position in the Cardiovascular Stem Cell Therapy Industry
Date:8/18/2009

in the recently FDA cleared Phase I REGEN trial utilizing muscle derived stem cells transduced to express the SDF-1 protein.

The appointment of this team will enable Mr. Leonhardt to pursue the company's strategic initiatives with respect to strengthening and broadening the Company's technologies. To this end, he has resigned from the Board of Directors.

Of his more focused position, Howard Leonhardt goes on to say:

"As Founder, Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board I will remain fully dedicated to assuring that our products are superior to all others in treating and caring for heart failure patients and will continue to be the Company's ambassador in developing relationships worldwide with heart failure physicians."

Mr. Leonhardt emphasized that Bioheart is, in truth, "fully committed to being the 'Go To Technology Partner for Heart Failure Specialists and Their Patients.'"

About Bioheart, Inc.

Bioheart, Inc. is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell((R)), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derive
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
2. Bioheart, Inc. Announces Additional Funding Support
3. Bioheart, Inc. to Present at Red Chip Investor Conference in New York
4. Bioheart, Inc., Announces Letter of Intent to Acquire MEDICALGORITHMICS, Ltd.
5. Bioheart, Inc. Announces Financial Results for Second Quarter 2008
6. Bioheart, Inc. Announces Results of Annual Meeting
7. Bioheart, Inc., Announces Management Change
8. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
9. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
10. Bioheart, Inc., Added to Russell Microcap Index
11. Bioheart, Inc. to Transfer to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2013)... This training is ideal for those who will be ... industry or those who want to explore Agile and Scrum, ... topics that will be covered in the 1-day Agile and ... artifacts, and scrum simulation (optional). , The trainings will ... 28, 2013 , Click here to register for a class. ...
(Date:6/14/2013)... These couplings are LinkTech’s smallest connectors ... a new and improved “Easy Grip Barrel” that provides ... and reliable connection every time. , The LinkTech interchangeable ... medical applications such as blood pressure cuffs. ... with better, more reliable, high quality, and cost effective ...
(Date:6/14/2013)... (PRWEB) June 14, 2013 Rosacea is said ... acne affects nearly 17 million; combined, it seems that most ... conditions mentioned. As U.S. News reports, often deciphering ... difficult as they all seem to have similar symptoms. Probiotic ... advice on how to treat them effectively. , Rosacea, Acne ...
(Date:6/14/2013)... , June 14, 2013  The Pittsburgh Life ... and levels of investment that were necessitated by delays ... overall investment climate and the uncertainty of state funding. ... said, "As the region,s only pure life sciences ... approved by the PLSG Board of Directors, were necessary ...
Breaking Biology Technology:Affordable Scrum Trainings in Denver, CO – 8 PDUs (June 28, 2013) by Conscires Agile Practices 2LinkTech Inc. Launches Ideal Replacement for a Luer Fitting 2LinkTech Inc. Launches Ideal Replacement for a Luer Fitting 3Rosacea, Acne, or Eczema? Probiotic Action Offers a Topical Probiotic to Treat the Most Common Skin Conditions 2Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding 2
... adds new line of heart disease and diabetes ... 20 Atherotech, Inc. ... Cholesterol Test in booth #912 at Internal Medicine ... College of Physicians (ACP). The conference takes place ...
... Proof of Mechanism of a Potential Oral Antagonist for ... Amira Pharmaceuticals, Inc., announced today the initiation of ... discovered oral drug candidate for the treatment and control ... acid pathway.AM211 is an oral, selective antagonist of the ...
... Data are New Releases for the Company Building ... Discoveries --DENVER, April 20 DXL625 ... antibodies in their ability to attach and deplete ... research conducted at InNexus Biotechnology Inc. (Toronto Stock ...
Cached Biology Technology:Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia 2Atherotech to Exhibit its VAP(R) Cholesterol Test at Internal Medicine 2009 in Philadelphia 3Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist 2AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 2AACR 100th Annual Meeting Highlights Superior Ability of InNexus' DXL-Modified Anti-CD20 Antibody to Attach and Kill NHL With Safety Comparable to Approved Antibody Therapies in Preclinical Studies 3
(Date:6/14/2013)... the only ones tending their gardens. , At the ... ants cultivate thriving communities of fungi and bacteria using ... are a source of food and shelter for the ... biofuel production. , "We are interested in the whole ... goes in and is converted to energy for the ...
(Date:6/14/2013)... By identifying a protein that acts as a ... have solved the mystery of why some infants are ... and major deformities of the skin and limbs, while ... little or no sign of the illness, called EEC. ... It is rare in its full-blown form, although individual ...
(Date:6/14/2013)... Data presented at EULAR 2013, the Annual Congress of ... biomarkers could significantly improve diagnosis in rheumatoid arthritis (RA). ... and UH-RA.21 were investigated; as a group they ... both early and seronegative disease, with 36% of ... patients testing positive. , RA is a chronic ...
Breaking Biology News(10 mins):Researchers unearth bioenergy potential in leaf-cutter ant communities 2Researchers unearth bioenergy potential in leaf-cutter ant communities 3CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 2CSHL geneticists solve mystery of EEC Syndrome's variable severity in children 3
... The best place to enjoy a breath of fresh air may ... A team of graduating seniors has created a system for public ... lead to tuberculosis (TB), flu and pneumonia. The CityBusters ... Chen, all seniors have installed a $500 device on a ...
... significantly slow the pace of climate change with practical ... bringing successful Western technologies to the developing world, according ... Foreign Affairs . For the last two ... to make progress. Part of the problem, the ...
... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... its first quarter ended March 31, 2012.  Revenues ... of 10% compared to $6.4 million in the same quarter last ... million, or $0.05 per diluted share. These results compared to net ...
Cached Biology News:College students work to sterilize air, kill pathogens on buses 2College students work to sterilize air, kill pathogens on buses 3College students work to sterilize air, kill pathogens on buses 4UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 2UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 3UCSD researchers: Where international climate policy has failed, grassroots efforts can succeed 4Aware, Inc. Reports First Quarter 2012 Financial Results 2Aware, Inc. Reports First Quarter 2012 Financial Results 3Aware, Inc. Reports First Quarter 2012 Financial Results 4Aware, Inc. Reports First Quarter 2012 Financial Results 5
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
This SMAD antibody sampler pack contains 5 Polyclonal ,SMAD antibodies....
Phosphate-Buffered Saline (PBS) 7.4 (1X) liquid...
Biology Products: